Pure Global AI
NCT06280716Not yet recruiting

A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 3 Trial to Investigate the Efficacy and Safety of Lebrikizumab When Used With/Without Topical Corticosteroid Treatment in Participants With Moderate-To-Severe Atopic Dermatitis
Eli Lilly and CompanyPhase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Atopic Dermatitis
Drug/Device/Intervention
Placebo
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Eli Lilly and Company
Location
Wuhu,Beijing,Beijing,Beijing,Beijing,Beijing,Beijing,Beijing,Beijing,Chongqing,Xiamen,Guangzhou,Guangzhou,Shenzhen,Shenzhen,Shenzhen,Shenzhen,Haikou,Wuhan,Wuhan,Wuhan,Changsha,Changsha,Changsha,Suzhou, China,South Korea
Timeline & enrollment
Phase
Phase 3
Start date
May 06, 2024
End date
Nov 04, 2026
Enrollment
430 participants
Primary outcome

Percentage of Participants Achieving Eczema Area and Severity Index (EASI-75) (≥75% Reduction in EASI Score) at Week 16 for Mono Cohort,Percentage of Participants Achieving EASI-75 at Week 16 for Combo Cohort

Summary

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab
 with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic
 Dermatitis. The study will last approximately 62 weeks.

ICD-10 classifications
Atopic dermatitisAtopic dermatitis, unspecifiedOther atopic dermatitisAcute atopic conjunctivitisAllergic contact dermatitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06280716
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06280716 through Pure Global AI's free database. This Phase 3 trial is sponsored by Eli Lilly and Company and is currently Not yet recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 430 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.